RxUtility

Cover Block

PUBLIC

Field	Value
Name	RxUtility
Tagline	Healthcare technology providing real-time access to copay assistance and prescription pricing data for affordability
Headquarters	Nashville, TN
Business Model	API / Developer Platform
Industry	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder

Links

PUBLIC

• Website: https://rxutility.com
• LinkedIn: https://www.linkedin.com/company/rxutility
• Founder LinkedIn (Miriam Paramore): https://www.linkedin.com/in/miriamparamore/

Executive Summary

PUBLIC

RxUtility is a Nashville-based health IT company that operates a real-time API exposing aggregated manufacturer copay coupons and cash-discount pharmacy pricing to providers, pharmacists, employers, payers, and digital health partners [Business Wire, Feb 2026]. The company's core thesis is that prescription abandonment is primarily a price-discovery problem at the point of care, a thesis backed by its own December 2025 report citing 98 million prescriptions abandoned annually in the United States due to cost [Business Wire, Dec 2025]. The product is positioned as infrastructure rather than a consumer brand: a single endpoint that returns the lowest available out-of-pocket price across coupon, cash, and discount-card paths, intended to be embedded inside existing pharmacy and provider workflows [RxUtility]. Founder and CEO Miriam Paramore brings a directly relevant operating record, having previously served as President of OptimizeRx (a public health IT company focused on point-of-care medication affordability) and prior senior roles at Emdeon, PDX, and Lucro [GlobeNewswire, Jul 2017] [Fierce Healthcare]. Funding details, round history, and investor syndicate are not publicly disclosed, which makes capitalization the most material open question for outside investors. Early commercial validation is visible through a February 2026 partnership with Buzz Health to widen consumer-facing price transparency [Business Wire, Feb 2026]. Over the next 12 to 18 months, the items worth tracking are API customer announcements (PBM, EHR, or pharmacy-chain integrations), any disclosed financing round, and whether the Buzz Health partnership produces measurable consumer adoption metrics.

Data Accuracy: GREEN -- Confirmed by Business Wire, GlobeNewswire, and the RxUtility company site.

Taxonomy Snapshot

Axis	Value
Business Model	API / Developer Platform
Industry / Vertical	Healthtech, prescription affordability
Technology Type	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder

Company Overview

PUBLIC

RxUtility presents itself as a purpose-built infrastructure layer for prescription affordability, headquartered in Nashville, Tennessee, a city that has become a meaningful secondary hub for health IT companies adjacent to provider and payer customers [RxUtility]. The founding date is not disclosed in public filings or press surfaced in this review, and the company has not published a stage label (seed, Series A, or otherwise). What is publicly verifiable is the leadership: Miriam Paramore is named as CEO and founder in the December 2025 announcement of the company's prescription abandonment report [Business Wire, Dec 2025], and her LinkedIn profile lists RxUtility alongside an entity called Invest Ahead [LinkedIn].

The most concrete public milestones in the company's short visible history are two press events. In December 2025, RxUtility published a report quantifying prescription abandonment due to cost at 98 million scripts per year in the United States, a release that doubles as the company's first significant thought-leadership push [Business Wire, Dec 2025]. In February 2026, RxUtility announced a partnership with Buzz Health to extend medication price transparency to consumers, distributed across Business Wire, Morningstar, and Yahoo Finance [Business Wire, Feb 2026] [Morningstar, Feb 2026] [Yahoo Finance, Feb 2026]. Beyond these two announcements, the public record is thin, which is consistent with a company in an early commercial phase that is selectively publicizing partnerships rather than running a broad press strategy.

Data Accuracy: YELLOW -- Founding date and legal entity not confirmed; leadership and recent milestones confirmed across two or more outlets.

Product and Technology

MIXED

The RxUtility product, as described on the company's own getstarted page, is a real-time prescription pricing data API that returns copay coupon eligibility and cash discount pricing at the pharmacy level, designed to be called inside provider e-prescribing flows or pharmacy dispensing workflows [RxUtility]. The company's about page describes two underlying datasets: an aggregated database of all manufacturer copay coupons, and real-time cash discount card pricing at every pharmacy [RxUtility]. The pitch in the February 2026 partnership release goes one step further, positioning RxUtility as "the only company to connect providers, pharmacists, employers, payers and digital health partners with real-time access" to that combined dataset [Business Wire, Feb 2026]. That sole-source claim is the company's, and outside investors should test it against incumbents in eligibility and price-transparency tooling before treating it as established fact.

The technical architecture is not publicly documented in detail. There are no GitHub repositories, developer docs, or job postings surfaced in this review that would allow inference of the underlying stack. The product surface area implied by the website (an HTTP API returning structured pricing and eligibility responses, with use cases spanning pharmacy workflow automation and provider-facing affordability checks) is consistent with a conventional REST or GraphQL service backed by a normalized coupon and pricing database (inferred from product descriptions, not from job postings). The company describes itself as Software (Non-AI), and nothing in the public material claims a machine-learning differentiator; the moat narrative rests on data aggregation completeness and real-time freshness rather than on model quality.

Use cases listed on the site span automated copay savings application, drug-cost reduction for self-funded employers, and pharmacy workflow integration [RxUtility]. The Buzz Health partnership extends the same API into a consumer-facing transparency surface, which suggests RxUtility intends to monetize the underlying dataset across both B2B (embedded) and B2B2C (partner-distributed) channels [Business Wire, Feb 2026].

Data Accuracy: YELLOW -- Product features confirmed by company site and partnership press; technical architecture not independently verified.

Market Research and Opportunity

PUBLIC

Prescription affordability has moved from a consumer-finance footnote to a board-level concern for payers, employers, and pharmacy chains, and the timing of RxUtility's market entry sits squarely on that shift. The company's own December 2025 report puts annual U.S. prescription abandonment due to cost at 98 million scripts [Business Wire, Dec 2025]. That figure, while sourced to RxUtility itself, is directionally consistent with long-running industry literature on cost-related medication non-adherence and frames the addressable problem in plain terms: nearly 100 million dispensing events per year where a real-time price or coupon lookup could potentially convert an abandoned script into a filled one.

Demand drivers are several and reinforcing. Self-insured employers are under pressure to control specialty drug spend; PBMs face regulatory and political scrutiny over rebate opacity; and federal policy on drug pricing transparency (including the ongoing implementation of hospital and payer price transparency rules) has normalized the expectation that prices should be visible at the point of decision. Manufacturer copay assistance programs, which are RxUtility's primary aggregated dataset, are themselves a multi-billion-dollar annual subsidy flow that is poorly surfaced at the point of prescribing. The opportunity for an infrastructure player is to be the connective tissue that makes those subsidies actually reach the patient before abandonment occurs.

Sizing claim	Value	Source
U.S. prescriptions abandoned annually due to cost	98 million	[Business Wire, Dec 2025]

98 million abandoned scripts is the single quantified anchor available, and even at a small per-script monetization assumption it implies an addressable revenue pool measured in the hundreds of millions of dollars (estimated). Adjacent and substitute markets include consumer discount-card brands (GoodRx and similar), PBM-owned price tools, EHR-embedded benefits-check vendors, and manufacturer hub services. Regulatory exposure cuts both ways: tighter rules on copay accumulators or PBM rebate practices could either expand the value of independent coupon aggregation or compress it, depending on how reform lands.

Data Accuracy: YELLOW -- Single quantified data point, sourced to a company-published report; demand drivers corroborated by general industry context but not by a named third-party market study in this review.

Competitive Landscape

MIXED

RxUtility competes in a crowded prescription-economics stack where the boundaries between coupon aggregator, discount-card brand, price-transparency tool, and benefits-check vendor are blurry.

The segment splits roughly into three groups. The first is consumer-facing discount and coupon brands, the most prominent of which is GoodRx, a publicly traded company with established pharmacy network economics and direct consumer demand. The second is point-of-prescribing benefits-check and real-time prescription benefit tools, a category historically served by Surescripts and by EHR-embedded vendors that surface formulary and copay data inside the prescriber workflow. The third, and the segment most directly analogous to RxUtility, is the point-of-care medication affordability stack inhabited by OptimizeRx, the publicly traded company where founder Miriam Paramore previously served as President [GlobeNewswire, Jul 2017]. OptimizeRx focuses heavily on manufacturer-sponsored messaging and affordability triggers delivered through EHRs, which overlaps RxUtility's coupon-distribution thesis directly.

Where RxUtility's edge appears most defensible today is in two places. First, the founder's prior operating role gives unusual insight into the manufacturer-coupon distribution mechanic, which is a relationship-and-contracts game more than a technology game [Fierce Healthcare]. Second, the API-first packaging is a genuine differentiator versus incumbents whose products are bundled into broader EHR or PBM contracts; a clean developer surface is a credible wedge into digital health partners and self-insured employer tooling [RxUtility]. The perishable side of those edges: relationship advantages decay if competitors hire the same talent, and API-first positioning is easy to copy once a category leader decides to expose endpoints.

Where the company is most exposed is on capital and distribution scale. GoodRx owns consumer brand and pharmacy negotiation use that RxUtility cannot match directly, and Surescripts sits inside the prescribing workflow at a scale no startup can replicate organically. The most plausible 18-month scenario: RxUtility wins if a major digital health platform or self-insured employer aggregator adopts the API as default infrastructure, validating the embedded-distribution thesis; it loses ground if OptimizeRx or a PBM ships an equivalent real-time coupon API bundled into existing contracts before RxUtility lands a marquee customer.

Data Accuracy: ORANGE -- Competitor set inferred from category knowledge rather than from named comparisons in the cited sources.

Opportunity

PUBLIC

If RxUtility executes, the prize is to become the default real-time price-and-coupon API that sits underneath every consumer touchpoint where a prescription gets priced.

The headline opportunity. The company's most plausible large outcome is to become embedded infrastructure for prescription affordability, the equivalent role that eligibility-check vendors play in medical claims or that payment processors play in commerce. The cited evidence makes that outcome reachable rather than aspirational for two reasons: the underlying problem is quantified at 98 million abandoned scripts per year [Business Wire, Dec 2025], and the company has already shown it can sign a distribution partner (Buzz Health) that extends its API into a consumer-facing surface without RxUtility having to build the consumer brand itself [Business Wire, Feb 2026]. The founder's prior tenure running a public-company analog gives the company unusual credibility with the manufacturer and pharmacy counterparties whose data and relationships are the moat [GlobeNewswire, Jul 2017].

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Embedded API for digital health	RxUtility becomes the default pricing API for telehealth, DPC, and digital pharmacy platforms	Repeat of the Buzz Health pattern with 5 to 10 named partners	The Buzz Health deal demonstrates the integration motion works [Business Wire, Feb 2026]
Self-insured employer wedge	RxUtility lands inside benefits-administration platforms that serve Fortune 1000 self-insured employers	A benefits-platform partnership or a marquee employer pilot	Employer pressure on Rx spend is a documented top-three benefits cost driver
Pharmacy workflow standard	Independent and regional pharmacy chains adopt the API to surface lowest-price options at the counter	A pharmacy software vendor integration	Founder's prior PDX (retail pharmacy IT) experience is directly relevant [Fierce Healthcare]

What compounding looks like. The flywheel for an aggregation API is straightforward: more integration partners produce more lookups, which justifies deeper data-licensing relationships with manufacturers and pharmacy networks, which improves coupon coverage and price freshness, which makes the API more valuable to the next integration partner. The Buzz Health partnership is the first visible turn of that wheel [Business Wire, Feb 2026]. If RxUtility can convert the December 2025 abandonment report into ongoing primary-research cadence, it also acquires a thought-leadership flywheel that lowers the cost of every subsequent enterprise sales conversation.

The size of the win. A credible public comparable is OptimizeRx, the point-of-care medication affordability company where the founder previously served as President [GlobeNewswire, Jul 2017]. OptimizeRx has traded as a public company with a market capitalization in the low-to-mid hundreds of millions of dollars in recent years (scenario, not a forecast). If RxUtility captures even a meaningful minority of the embedded-API segment of that same affordability stack, an outcome in a comparable market-cap range is internally consistent with the cited evidence (scenario, not a forecast). The upside case, in which RxUtility becomes the standard pricing-and-coupon API across digital health, employer, and pharmacy channels, would imply a valuation outcome materially above that comparable; the downside case, in which incumbents ship competing APIs first, would compress it.

Data Accuracy: YELLOW -- Scenarios anchored to one confirmed partnership, one company-published market data point, and one named public comparable.

Sources

PUBLIC

1. [RxUtility] Lower Prescription Costs with RxUtility API Integration | https://rxutility.com/getstarted

2. [RxUtility] About | https://rxutility.com/about

3. [RxUtility] Use Cases | https://rxutility.com/usecases

4. [RxUtility] Speaker Bio: Miriam Paramore | https://rxutility.com/speaker-bio---miriam-paramore

5. [LinkedIn] RxUtility company page | https://www.linkedin.com/company/rxutility

6. [LinkedIn] Miriam Paramore profile | https://www.linkedin.com/in/miriamparamore/

7. [Business Wire, Feb 2026] RxUtility and Buzz Health Partner to Boost Medication Price Transparency for Consumers | https://www.businesswire.com/news/home/20260203078211/en/RxUtility-and-Buzz-Health-Partner-to-Boost-Medication-Price-Transparency-for-Consumers

8. [Morningstar, Feb 2026] RxUtility and Buzz Health Partner to Boost Medication Price Transparency for Consumers | https://www.morningstar.com/news/business-wire/20260203078211/rxutility-and-buzz-health-partner-to-boost-medication-price-transparency-for-consumers

9. [Yahoo Finance, Feb 2026] RxUtility and Buzz Health Partner to Boost Medication Price Transparency for Consumers | https://finance.yahoo.com/news/rxutility-buzz-health-partner-boost-141500365.html

10. [Business Wire, Dec 2025] Americans Abandon 98 Million Prescriptions Annually Due to Cost, Finds New RxUtility Report | https://www.businesswire.com/news/home/20251203584551/en/Americans-Abandon-98-Million-Prescriptions-Annually-Due-to-Cost-Finds-New-RxUtility-Report

11. [GlobeNewswire, Jul 2017] OptimizeRx Appoints Health IT Industry Veteran, Miriam Paramore, as President | https://www.globenewswire.com/news-release/2017/07/31/1064917/0/en/OptimizeRx-Appoints-Health-IT-Industry-Veteran-Miriam-Paramore-as-President-Paramore-to-Drive-Scale-as-OptimizeRx-Offers-Medication-Savings-at-Point-of-Care.html

12. [Fierce Healthcare] Miriam Paramore author profile | https://www.fiercehealthcare.com/person/miriam-paramore

13. [Outcomes Rocket Podcast] Making Medications Affordable and Ensuring Compliance with Miriam Paramore | https://anchor.fm/outcomesrocket/episodes/Making-Medications-Affordable-and-Ensuring-Compliance-with-Miriam-Paramore--President-of-OptimizeRx-eduhrv